XML 23 R9.htm IDEA: XBRL DOCUMENT v3.23.1

CASH AND CASH EQUIVALENTS AND MARKETABLE SECURITIES

12 Months Ended

Dec. 31, 2022

Cash and Cash Equivalents [Abstract]

CASH AND CASH EQUIVALENTS AND MARKETABLE SECURITIES

NOTE 3 – CASH AND CASH EQUIVALENTS AND MARKETABLE SECURITIES

The following table sets forth our cash, cash equivalents and marketable securities as of December 31, 2022 and 2021:

SCHEDULE OF CASH AND CASH EQUIVALENTS AND MARKETABLE SECURITIES 

		2022				2021
		As of December 31,
		2022				2021
Cash and cash equivalents:
Cash		$	1,195			$	13,493
U.S. treasury securities			1,247				-
Total cash and cash equivalents		$	2,442			$	13,493
Marketable securities:
Money market mutual funds		$	1,999			$	1,999
U.S. treasury securities			3,761				-
Total marketable securities		$	5,760			$	1,999
Total cash and cash equivalents and marketable securities		$	8,202			$	15,492

The unrealized gains on our marketable securities were $12 and less than $1 for the years ended December 31, 2022 and 2021, respectively.

Treasuries have contractual maturities of less than 12 months.

MICROBOT MEDICAL INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands

(Except share and per share data)

X

- References

No definition available.

+ Details

Name:	us-gaap_CashAndCashEquivalentsAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-URI https://asc.fasb.org/topic&trid=2196928

+ Details

Name:	us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration